Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
June 03, 2021 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
May 25, 2021 07:00 ET
|
Apellis Pharmaceuticals, Inc.
EMPAVELI demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization (p<0.0001) and reduction in lactate dehydrogenase (LDH) (p<0.0001) compared to standard of...
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
May 14, 2021 18:25 ET
|
Apellis Pharmaceuticals, Inc.
EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are: Treatment naïveSwitching from C5 inhibitor Soliris® (eculizumab) Switching from C5 inhibitor Ultomiris®...
Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress
May 12, 2021 10:06 ET
|
Apellis Pharmaceuticals, Inc.
Seven accepted abstracts, including an oral presentation, reinforce the potential of pegcetacoplan, an investigational, targeted C3 therapy, to redefine treatment for patients with paroxysmal...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2021 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results
April 28, 2021 16:01 ET
|
Apellis Pharmaceuticals, Inc.
Marketing application for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA target action date of May 14,...
Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021
April 21, 2021 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis to Showcase Leadership in Retina at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 16, 2021 12:44 ET
|
Apellis Pharmaceuticals, Inc.
10 accepted abstracts include five oral presentations from pioneering artificial intelligence (AI) collaboration Presentations support the potential of intravitreal pegcetacoplan, an investigational...
Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy
April 13, 2021 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at 24 months (p=0.007)Top-line data from Phase 3 DERBY...
Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
March 17, 2021 17:48 ET
|
Apellis Pharmaceuticals, Inc.; Sobi
Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels...